Physician profile
Faiaz Rasul
NPI 1942313010
$16,168.55
in general payments reported to CMS, 2019-2025
49 companies · $1,601 in 2025
The $1,601 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,683 · 2020: $1,222 · 2021: $3,822 · 2022: $1,996 · 2023: $2,189 · 2024: $1,655 · 2025: $1,601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,446.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $5,638.19 | 2019-2025 | Xarelto, Spravato |
| Biohaven Pharmaceuticals, INC. | $1,267.68 | 2021 | |
| Abbvie INC. | $1,151.59 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,020.02 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $883.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $844.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $616.84 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $465.41 | 2019-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $439.11 | 2019-2025 | |
| Amgen INC. | $420.21 | 2019-2025 | Repatha, Otezla, Otezla |
| Ucb, INC. | $303.43 | 2019-2025 | Briviact |
| Pfizer INC. | $260.26 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $218.93 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $198.99 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $180.47 | 2019-2023 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiaz Rasul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.